• Citer

Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis.

par De Gottardi, Andrea;Trebicka, Jonel;Klinger, Christoph;Plessier, Aurelie;Seijo, Susana;Terziroli, Benedetta;Magenta, Lorenzo;Semela, David;Buscarini, Elisabetta;Langlet, Philippe ;Görtzen, Jan;Puente, Angela;Müllhaupt, Beat;Navascuès, Carmen;Nery, Filipe;Deltenre, Pierre ;Turon, Fanny;Engelmann, Cornelius;Arya, Rupen;Caca, Karel;Peck-Radosavljevic, Markus;Leebeek, Frank W G;Valla, Dominique;Garcia-Pagan, Juan Carlos;VALDIG Investigators,
Référence Liver international, 37, 5, page (694-699)
Publication Publié, 2017-05

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Direct-acting oral anticoagulants (DOACs) are used in patients with splanchnic vein thrombosis (SVT) and cirrhosis, but evidence for safety and efficacy in this setting is limited. Our aim was to identify indications and reasons for starting or switching to DOACs and to report adverse effects, complications and short-term outcome.